Literature DB >> 8586704

Identification and antimicrobial resistance patterns of clinical isolates of Clostridium clostridioforme, Clostridium innocuum, and Clostridium ramosum compared with those of clinical isolates of Clostridium perfringens.

C J Alexander1, D M Citron, J S Brazier, E J Goldstein.   

Abstract

Clostridium ramosum, C. innocuum, and C. clostridioforme are frequently isolated from clinical specimens including blood. Because of Gram stain variability, a lack of spores, and atypical colonial morphology, identification of these species is often difficult. Three anaerobe identification kits were evaluated for their abilities to identify these species. For comparison, 11 strains of C. perfringens were evaluated in parallel. By using profile numbers and codebooks, the correct genus and species were identified, as follows: with the RapID ANA II kit, 100% (20 of 20) of C. ramosum isolates, 24% (5 of 21) of C. innocuum isolates, and 50% (10 of 20) of C. clostridioforme isolates; with the AnIDent kit, 60% (12 of 20) of C. ramosum isolates, 28% (6 of 21) of C. innocuum isolates, and 90% (18 of 20) of C. clostridioforme isolates; with the ATB32A kit, 70% (14 of 20) of C. ramosum isolates, 0% (0 of 21) of C. innocuum isolates, and 40% (8 of 20) of C. clostridioforme isolates. Profile numbers that overlapped several species were obtained as follows: with the RapID ANA II kit, 0% of C. ramosum isolates, 76% of C. innocuum isolates, and 40% of C. clostridioforme isolates; with the AnIDent kit 40% of C. ramosum isolates, 62% of C. innocuum isolates, and 5% of C. clostridioforme isolates; with the ATB32A kit, 15% of C. ramosum isolates, 52% of C. innocuum isolates, and 25% of C. clostridioforme isolates. One strain of C. innocuum was misidentified by the AnIDent kit, and the remainder yielded profile numbers that were not listed in the codebooks. The MICs of 11 antimicrobial agents including penicillin G, metronidazole, clindamycin, cefoxitin, cefotetan, imipenem, meropenem, amoxicillin-clavulanate, ampicillin-sulbactam, piperacillin-tazobactam, and vancomycin were determined by the agar dilution method. All C. perfringens strains were susceptible to all antimicrobial agents tested. Various levels of resistance to cefoxitin, cefotetan, and penicillin G were noted with C. ramosum, C. clostridioforme, and C. innocuum. In addition, resistance to clindamycin was noted with C. ramosum (5%) and C. innocuum (10%). Most strains of C. innocuum were only moderately susceptible to vancomycin (MIC at which 90% of strains are inhibited, 4 micrograms/ml).

Entities:  

Mesh:

Year:  1995        PMID: 8586704      PMCID: PMC228675          DOI: 10.1128/jcm.33.12.3209-3215.1995

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  12 in total

1.  Evaluation of the new RapID-ANA II system for the identification of clinical anaerobic isolates.

Authors:  L M Marler; J A Siders; L C Wolters; Y Pettigrew; B L Skitt; S D Allen
Journal:  J Clin Microbiol       Date:  1991-05       Impact factor: 5.948

2.  Clinical evaluation of the RapID-ANA II panel for identification of anaerobic bacteria.

Authors:  D M Celig; P C Schreckenberger
Journal:  J Clin Microbiol       Date:  1991-03       Impact factor: 5.948

3.  Evaluation of the ATB 32 A system for identification of anaerobic bacteria isolated from clinical specimens.

Authors:  W J Looney; A J Gallusser; H K Modde
Journal:  J Clin Microbiol       Date:  1990-07       Impact factor: 5.948

4.  Comparative activity of several beta-lactam antibiotics against anaerobes determined by two methods.

Authors:  R J Zabransky; R J Birk
Journal:  Clin Ther       Date:  1987       Impact factor: 3.393

5.  Comparison of the PRAS II, AN-Ident, and RapID-ANA systems for identification of anaerobic bacteria.

Authors:  R S Burlage; P D Ellner
Journal:  J Clin Microbiol       Date:  1985-07       Impact factor: 5.948

6.  Accuracy and reproducibility of a four-hour method for anaerobe identification.

Authors:  P C Appelbaum; C S Kaufmann; J W Depenbusch
Journal:  J Clin Microbiol       Date:  1985-06       Impact factor: 5.948

Review 7.  Rapid methods for identification of clinical isolates of Gram-negative anaerobic bacilli.

Authors:  V O Rotimi; J Faulkner; B I Duerden
Journal:  Med Lab Sci       Date:  1980-10

8.  Comparative susceptibility of the Bacteroides fragilis group species and other anaerobic bacteria to meropenem, imipenem, piperacillin, cefoxitin, ampicillin/sulbactam, clindamycin and metronidazole.

Authors:  E J Goldstein; D M Citron; C E Cherubin; S L Hillier
Journal:  J Antimicrob Chemother       Date:  1993-03       Impact factor: 5.790

9.  Susceptibility of anaerobic bacteria to 23 antimicrobial agents.

Authors:  V L Sutter; S M Finegold
Journal:  Antimicrob Agents Chemother       Date:  1976-10       Impact factor: 5.191

10.  Survey of anaerobic susceptibility patterns in Canada.

Authors:  A M Bourgault; G K Harding; J A Smith; G B Horsman; T J Marrie; F Lamothe
Journal:  Antimicrob Agents Chemother       Date:  1986-11       Impact factor: 5.191

View more
  17 in total

1.  Secondary infection of intracranial hydatid cyst with Clostridium ramosum.

Authors:  Omer Faruk Turkoglu; Ihsan Solaroglu; Kagan Tun; Etem Beskonakli; Yamac Taskin
Journal:  Childs Nerv Syst       Date:  2004-12-04       Impact factor: 1.475

2.  Clostridium aldenense sp. nov. and Clostridium citroniae sp. nov. isolated from human clinical infections.

Authors:  Yumi A Warren; Kerin L Tyrrell; Diane M Citron; Ellie J C Goldstein
Journal:  J Clin Microbiol       Date:  2006-07       Impact factor: 5.948

3.  Conservation and Evolution of the Sporulation Gene Set in Diverse Members of the Firmicutes.

Authors:  Michael Y Galperin; Natalya Yutin; Yuri I Wolf; Roberto Vera Alvarez; Eugene V Koonin
Journal:  J Bacteriol       Date:  2022-05-31       Impact factor: 3.476

4.  Spondylodiscitis due to Clostridium ramosum infection in an immunocompetent elderly patient.

Authors:  Jean-Philippe Lavigne; Nicole Bouziges; Albert Sotto; Jean-Louis Leroux; Sylvie Michaux-Charachon
Journal:  J Clin Microbiol       Date:  2003-05       Impact factor: 5.948

5.  Low-level vancomycin resistance in Clostridium innocuum.

Authors:  F Mory; A Lozniewski; V David; J P Carlier; L Dubreuil; R Leclercq
Journal:  J Clin Microbiol       Date:  1998-06       Impact factor: 5.948

6.  In vitro activities of daptomycin, vancomycin, quinupristin- dalfopristin, linezolid, and five other antimicrobials against 307 gram-positive anaerobic and 31 Corynebacterium clinical isolates.

Authors:  Ellie J C Goldstein; Diane M Citron; C Vreni Merriam; Yumi A Warren; Kerrin L Tyrrell; Helen T Fernandez
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

7.  Endospores and other lysis-resistant bacteria comprise a widely shared core community within the human microbiota.

Authors:  Sean M Kearney; Sean M Gibbons; Mathilde Poyet; Thomas Gurry; Kevin Bullock; Jessica R Allegretti; Clary B Clish; Eric J Alm
Journal:  ISME J       Date:  2018-06-13       Impact factor: 10.302

8.  Clostridium innocuum Bacteremia in a patient with acquired immunodeficiency syndrome.

Authors:  Nancy Crum-Cianflone
Journal:  Am J Med Sci       Date:  2009-06       Impact factor: 2.378

9.  Answer to January 2022 Photo Quiz.

Authors:  Kevin Sermet; Eric Kipnis; Claire Duployez; Frédéric Wallet; Rodrigue Dessein; Rémi Le Guern
Journal:  J Clin Microbiol       Date:  2022-01-19       Impact factor: 11.677

Review 10.  Clostridium innocuum: Microbiological and clinical characteristics of a potential emerging pathogen.

Authors:  Kathryn E Cherny; Emily B Muscat; Megan E Reyna; Larry K Kociolek
Journal:  Anaerobe       Date:  2021-07-28       Impact factor: 3.331

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.